The main finding of the present study was that canagliflozin treatment had no different effect on NT-proBNP concentration according to the baseline status of glucose-lowering agents in clinically stable patients with T2D and CHF (almost all with NYHA class I to II and HFpEF). The gene discussed is NPPB; the disease is congestive heart failure.